Journal of cardiology最新文献

Author's reply to "how to indicate left atrial posterior wall isolation adjunctive to conventional pulmonary vein isolation in patients with atrial fibrillation".

IF 2.5 3区医学

Journal of cardiology Pub Date : 2025-02-14 DOI: 10.1016/j.jjcc.2025.02.015

Zheng-Qi Song, Xin-Yu Lu, Yu-Peng Xu, Hui Lin, Yi-He Chen

引用次数: 0

Letter to the editor: Mitral regurgitation in atrial fibrillation: Is a simple repair enough to tackle a complex problem?

IF 2.5 3区医学

Journal of cardiology Pub Date : 2025-02-13 DOI: 10.1016/j.jjcc.2025.02.011

Hadisa Talpur, Ghulam Mustafa

引用次数: 0

TRP channels in cardiac mechano-redox coupling and diseases.

IF 2.5 3区医学

Journal of cardiology Pub Date : 2025-02-13 DOI: 10.1016/j.jjcc.2025.02.016

Xinya Mi, Di Wu, Tomoya Ito, Yuri Kato, Akiyuki Nishimura, Motohiro Nishida

引用次数: 0

Implications of asymptomatic hypotension for patients prescribed Sacubitril/valsartan: Insight from the REVIEW-HF registry.

IF 2.5 3区医学

Journal of cardiology Pub Date : 2025-02-13 DOI: 10.1016/j.jjcc.2025.02.012

Wataru Fujimoto, Shingo Matsumoto, Koshiro Kanaoka, Takahito Nasu, Keisuke Kida, Nobuyuki Kagiyama, Shunsuke Ishii, Yukihiro Watanabe, Atsushi Kikuchi, Takeshi Ijichi, Tatsuhiro Shibata, Hidekazu Tanaka

{"title":"Implications of asymptomatic hypotension for patients prescribed Sacubitril/valsartan: Insight from the REVIEW-HF registry.","authors":"Wataru Fujimoto, Shingo Matsumoto, Koshiro Kanaoka, Takahito Nasu, Keisuke Kida, Nobuyuki Kagiyama, Shunsuke Ishii, Yukihiro Watanabe, Atsushi Kikuchi, Takeshi Ijichi, Tatsuhiro Shibata, Hidekazu Tanaka","doi":"10.1016/j.jjcc.2025.02.012","DOIUrl":"https://doi.org/10.1016/j.jjcc.2025.02.012","url":null,"abstract":"Background: Sacubitril/valsartan has unequivocally demonstrated prognostic improvement in patients with chronic heart failure in large-scale randomized controlled trials. However, it remains uncertain whether patients presenting with asymptomatic hypotension have distinct prognoses compared to those with symptomatic hypotension, and there is no consensus on the optimal strategy for managing asymptomatic hypotension.Methods and results: A multicenter retrospective study was conducted, analyzing data from patients initiated on sacubitril/valsartan therapy. The primary outcome was a composite of cardiovascular death or a hospitalization for heart failure. Among 992 patients, 72 patients (7.3 %) experienced symptomatic hypotension, and 122 patients (12.3 %) experienced asymptomatic hypotension within three months. The incidence of primary endpoint for patients who experienced hypotension, regardless of whether it was symptomatic or asymptomatic, was higher than for those who did not experience hypotension (Log-rank p < 0.05). Among patients who experienced asymptomatic hypotension, 23 patients discontinued sacubitril/valsartan within three days after the onset of asymptomatic hypotension. Patients who discontinued sacubitril/valsartan after the occurrence of asymptomatic hypotension experienced a significantly higher incidence of primary endpoints compared to those who continued sacubitril/valsartan therapy (Log-rank p = 0.01).Conclusion: The prognosis of patients who discontinued sacubitril/valsartan after the occurrence of asymptomatic hypotension during sacubitril/valsartan therapy was poor. It may be beneficial to aim for the continuation of sacubitril/valsartan therapy even after the occurrence of asymptomatic hypotension.","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic values of atrial high-rate episodes on mortality risks in CIED patients.

IF 2.5 3区医学

Journal of cardiology Pub Date : 2025-02-13 DOI: 10.1016/j.jjcc.2025.02.010

Phuuwadith Wattanachayakul, Panat Yanpiset, Narathorn Kulthamrongsri, Vitchapong Prasitsumrit, Kevin Bryan Lo, Jakrin Kewcharoen, Sumeet Mainigi

{"title":"Prognostic values of atrial high-rate episodes on mortality risks in CIED patients.","authors":"Phuuwadith Wattanachayakul, Panat Yanpiset, Narathorn Kulthamrongsri, Vitchapong Prasitsumrit, Kevin Bryan Lo, Jakrin Kewcharoen, Sumeet Mainigi","doi":"10.1016/j.jjcc.2025.02.010","DOIUrl":"https://doi.org/10.1016/j.jjcc.2025.02.010","url":null,"abstract":"Background: Recent data showed that patients with cardiac implantable electronic devices (CIEDs) who have atrial high-rate episodes (AHRE) have an increased risk of systemic thromboembolism even without a history of atrial fibrillation. However, data regarding the impact of AHRE on mortality outcomes remain conflicting. This study aims to elucidate this relationship by summarizing all available data via systematic review and meta-analysis.Methods: We systematically reviewed MEDLINE and EMBASE from inception to May 2024 to evaluate the association between AHRE and mortality risk in patients with CIED who did not have a history of atrial fibrillation at implantation. We compared all-cause and cardiovascular mortality in patients with AHRE to those without AHRE. Relative risk (RR) or hazard ratio and their 95 % confidence intervals (CIs) were extracted from each study and combined using the generic inverse variance method.Results: A total of 15 cohort studies were included in the meta-analysis. The pooled analysis showed that patients with AHRE had a higher risk of all-cause mortality compared to those without AHRE, with a pooled RR of 1.57 (95 % CI 1.21-2.03; I2 = 67 %; p < 0.001). Similarly, AHRE was associated with higher cardiovascular mortality, with a pooled RR of 1.80 (95 % CI 1.06-3.05; I2 = 49 %; p = 0.03).Conclusions: Our study found that patients with CIEDs who developed AHRE were at a higher risk of all-cause and cardiovascular mortality compared to those without AHRE.","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of new anticoagulants targeting coagulation factor XI and prospects for clinical use.

IF 2.5 3区医学

Journal of cardiology Pub Date : 2025-02-13 DOI: 10.1016/j.jjcc.2025.02.013

Masahiro Ieko, Kazumasa Ohmura, Sumiyoshi Naito, Mika Yoshida, Osamu Kumano

{"title":"Development of new anticoagulants targeting coagulation factor XI and prospects for clinical use.","authors":"Masahiro Ieko, Kazumasa Ohmura, Sumiyoshi Naito, Mika Yoshida, Osamu Kumano","doi":"10.1016/j.jjcc.2025.02.013","DOIUrl":"https://doi.org/10.1016/j.jjcc.2025.02.013","url":null,"abstract":"Thrombosis is a potentially fatal condition for which various anticoagulant therapies have been used for prevention and treatment. However, bleeding events remain a concern with all anticoagulant drugs. Recent evidence suggests that inhibiting coagulation factor XI (FXI) and activated FXI (FXIa) plays a greater role in the formation of pathological thrombi in thrombosis than in normal hemostatic thrombi, allowing for the potential to address these two events separately. Consequently, FXI/XIa inhibition has become the focus of anticoagulant drug research, leading to the development of numerous FXI-targeting compounds with diverse mechanisms of action. Herein, we aimed to review FXI/FXIa inhibitors under development, discussing the role of FXI in the coagulation reaction and the advantages and disadvantages associated with its deficiency. The results of a Phase II study showed that FXI/XIa inhibitors provide efficacy comparable to that of low molecular weight heparin therapy while reducing clinically significant bleeding events. Additionally, in a study of patients with atrial fibrillation, FXI/XIa inhibitors reduced bleeding events compared to those with direct oral anticoagulants. Furthermore, when combined with antiplatelet therapy, FXI/XIa inhibitors did not significantly increase bleeding risk in non-cardioembolic stroke or acute coronary syndrome. However, conflicting trial results have also been reported, highlighting the difficulty in assessing the clinical benefit of FXI/XIa inhibitors in different clinical settings, such as atrial fibrillation and acute myocardial infarction. Future large, well-designed Phase III studies are needed to evaluate the safety and efficacy of FXI/XIa inhibitors across diverse populations requiring antithrombotic therapy.","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Paradoxical outcomes in very severe aortic stenosis following TAVI.

IF 2.5 3区医学

Journal of cardiology Pub Date : 2025-02-13 DOI: 10.1016/j.jjcc.2025.02.014

Mesut Gitmez, Mehmet Kadri Akboga

引用次数: 0

Cognitive impairment in patients with heart failure: Physiopathology, clinical implications, and therapeutic considerations.

IF 2.5 3区医学

Journal of cardiology Pub Date : 2025-02-12 DOI: 10.1016/j.jjcc.2025.02.007

Meng Li, Junping Zhang, Yue Hu, Yue Zhang

{"title":"Cognitive impairment in patients with heart failure: Physiopathology, clinical implications, and therapeutic considerations.","authors":"Meng Li, Junping Zhang, Yue Hu, Yue Zhang","doi":"10.1016/j.jjcc.2025.02.007","DOIUrl":"https://doi.org/10.1016/j.jjcc.2025.02.007","url":null,"abstract":"Cognitive impairment (CI) is a significant comorbidity in individuals with heart failure (HF). A substantial number of patients with HF may experience CI, which can present as deficits in attention, memory, executive function, and processing speed. HF patients with CI tend to have reduced functional independence, self-care capabilities, medication adherence and decision-making ability, along with more frequent rehospitalizations, and an increased risk of mortality. Currently, there is no established gold standard diagnostic tool or follow-up strategy for assessing CI in patients with HF. There has been an increasing recognition of the complex bidirectional relationship between HF and CI. However, the exact pathological mechanisms of CI in HF need further in-depth investigation. This review aims to explore the current epidemiological status of CI in patients with HF, the relationship between HF and cognitive dysfunction, the pathological mechanisms involved, as well as the early screening, diagnosis, and management issues for HF patients with CI. It also discusses prevention and intervention strategies. The objective is to provide a scientific basis for the clinical diagnosis, management, and treatment of CI in HF, while proposing future research directions to advance this field.","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors involved in discontinuation or dose reduction of angiotensin receptor-neprilysin inhibitor: A retrospective analysis in 200 patients.

IF 2.5 3区医学

Journal of cardiology Pub Date : 2025-02-12 DOI: 10.1016/j.jjcc.2025.02.006

Haruna Inoue, Kenzo Uzu, Yusuke Fukuyama, Yoshinori Nagasawa, Kiyohiro Hyogo, Yasushi Shimokawa, Hideaki Ookubo, Hiroki Shimizu

引用次数: 0

Imaging characteristics of patients with cardiac sarcoidosis who presented with ventricular arrhythmias.

IF 2.5 3区医学

Journal of cardiology Pub Date : 2025-02-12 DOI: 10.1016/j.jjcc.2025.02.004

Noor K Albakaa, Kimi Sato, Naoto Kawamatsu, Masayoshi Yamamoto, Tomoko Machino-Ohtsuka, Yuki Komatsu, Akihiko Nogami, Masaki Ieda, Tomoko Ishizu

{"title":"Imaging characteristics of patients with cardiac sarcoidosis who presented with ventricular arrhythmias.","authors":"Noor K Albakaa, Kimi Sato, Naoto Kawamatsu, Masayoshi Yamamoto, Tomoko Machino-Ohtsuka, Yuki Komatsu, Akihiko Nogami, Masaki Ieda, Tomoko Ishizu","doi":"10.1016/j.jjcc.2025.02.004","DOIUrl":"https://doi.org/10.1016/j.jjcc.2025.02.004","url":null,"abstract":"Background: Ventricular arrhythmia (VA) is an ominous manifestation of cardiac sarcoidosis (CS). Hence, identifying specific characteristics associated with VA in imaging modalities may enhance risk stratification.Methods: Fifty-nine patients diagnosed with CS were retrospectively studied and grouped based on presenting symptoms as the VA group (sustained ventricular tachycardia and ventricular fibrillation) and the non-VA group (atrioventricular block, heart failure, and other symptoms). Thirty-nine patients underwent comprehensive evaluation by cardiac magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for comparing cardiac involvement distribution.Results: The VA group (n = 15) showed higher prevalence of right bundle branch block, basal interventricular thinning, and left ventricle wall motion abnormality. In Cox analysis, VA at baseline (hazard ratio 4.75, p = 0.008) was associated with poor outcomes. The VA group showed a larger extent of late gadolinium enhancement than the non-VA group, especially in the left ventricular mid inferoseptal, right ventricular (RV) basal lateral to mid lateral, and RV apical anterior lesions. FDG-PET accumulation was prominent in the RV basal lateral to basal inferior, and mid anterior lesions in the VA group.Conclusions: Patients who presented with VA had worse outcomes and a larger cardiac involvement predominant to the RV and ventricular septum; RV predominant scar pattern may serve as a surrogate in patients with CS and explain possible correlation with electrophysiological abnormalities.","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0